155 related articles for article (PubMed ID: 19635186)
1. Should low-dose mycophenolate mofetil be used to prolong the response after rituximab therapy in patients with immune thrombocytopenic purpura? A case report.
Bruserud Ø; Håvardstein K
Hematology; 2009 Aug; 14(4):224-6. PubMed ID: 19635186
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura.
Provan D; Moss AJ; Newland AC; Bussel JB
Am J Hematol; 2006 Jan; 81(1):19-25. PubMed ID: 16369979
[TBL] [Abstract][Full Text] [Related]
3. Role of mycophenolate mofetil in remission maintenance after a successful response to rituximab.
Sharma AP; Filler G
Pediatr Nephrol; 2009 Feb; 24(2):423-4. PubMed ID: 18853197
[No Abstract] [Full Text] [Related]
4. Low rate of long-lasting remissions after successful treatment of immune thrombocytopenic purpura with rituximab.
Schweizer C; Reu FJ; Ho AD; Hensel M
Ann Hematol; 2007 Oct; 86(10):711-7. PubMed ID: 17622529
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for the treatment of refractory idiopathic thrombocytopenic purpura (ITP) and thrombotic thrombocytopenic purpura (TTP): report of three cases.
Koulova L; Alexandrescu D; Dutcher JP; O'Boyle KP; Eapen S; Wiernik PH
Am J Hematol; 2005 Jan; 78(1):49-54. PubMed ID: 15609292
[TBL] [Abstract][Full Text] [Related]
6. [Rituximab treatment for adults with steroid-resistant idiopathic thrombocytopenic purpura].
Wang W; Yu QH; Zhang HY; Chu XX; Chen F; Zhang CQ; Zhou YH; Hou M
Zhonghua Nei Ke Za Zhi; 2008 Mar; 47(3):225-7. PubMed ID: 18785508
[TBL] [Abstract][Full Text] [Related]
7. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adult refractory idiopathic thrombocytopenic purpura.
Braendstrup P; Bjerrum OW; Nielsen OJ; Jensen BA; Clausen NT; Hansen PB; Andersen I; Schmidt K; Andersen TM; Peterslund NA; Birgens HS; Plesner T; Pedersen BB; Hasselbalch HC
Am J Hematol; 2005 Apr; 78(4):275-80. PubMed ID: 15795920
[TBL] [Abstract][Full Text] [Related]
8. Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil.
Vasoo S; Thumboo J; Fong KY
Lupus; 2003; 12(8):630-2. PubMed ID: 12945723
[TBL] [Abstract][Full Text] [Related]
9. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura.
Hou M; Peng J; Shi Y; Zhang C; Qin P; Zhao C; Ji X; Wang X; Zhang M
Eur J Haematol; 2003 Jun; 70(6):353-7. PubMed ID: 12756016
[TBL] [Abstract][Full Text] [Related]
10. Rituximab is effective for selected patients with chronic steroid-refractory immune thrombocytopenic purpura.
Lalayanni C; Stavroyianni N; Saloum R; Tsompanakou A; Anagnostopoulos A
Hematology; 2004 Aug; 9(4):287-9. PubMed ID: 15621736
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura.
Zhang WG; Ji L; Cao XM; Chen YX; He AL; Liu J; Zhao WH; Zou SP
Acta Pharmacol Sin; 2005 May; 26(5):598-602. PubMed ID: 15842780
[TBL] [Abstract][Full Text] [Related]
12. Rituximab therapy for chronic and refractory immune thrombocytopenic purpura: a long-term follow-up analysis.
Garcia-Chavez J; Majluf-Cruz A; Montiel-Cervantes L; Esparza MG; Vela-Ojeda J;
Ann Hematol; 2007 Dec; 86(12):871-7. PubMed ID: 17874322
[TBL] [Abstract][Full Text] [Related]
13. Very long-term remission induced by short-term rituximab monotherapy in a patient with heavily pretreated, chronic immune thrombocytopenic purpura.
Clausen MR; Segel E; Brandsborg M; d'Amore F
Eur J Haematol; 2011 Mar; 86(3):256-9. PubMed ID: 21166717
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of mycophenolate mofetil in adult refractory auto-immune cytopenias: a single center preliminary study.
Kotb R; Pinganaud C; Trichet C; Lambotte O; Dreyfus M; Delfraissy JF; Tchernia G; Goujard C
Eur J Haematol; 2005 Jul; 75(1):60-4. PubMed ID: 15946312
[TBL] [Abstract][Full Text] [Related]
15. Refractory pemphigus vulgaris treated with rituximab and mycophenolate mofetil.
Biot Sdel R; Franco JP; Lima RB; Pereira HN; Marques LP; Martins CJ
An Bras Dermatol; 2014; 89(6):980-4. PubMed ID: 25387507
[TBL] [Abstract][Full Text] [Related]
16. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura.
Stasi R; Pagano A; Stipa E; Amadori S
Blood; 2001 Aug; 98(4):952-7. PubMed ID: 11493438
[TBL] [Abstract][Full Text] [Related]
17. Rituximab (anti-CD20 monoclonal antibody) in children with chronic refractory symptomatic immune thrombocytopenic purpura: efficacy and safety of treatment.
Parodi E; Nobili B; Perrotta S; Rosaria Matarese SM; Russo G; Licciardello M; Zecca M; Locatelli F; Cesaro S; Bisogno G; Giordano P; De Mattia D; Ramenghia U
Int J Hematol; 2006 Jul; 84(1):48-53. PubMed ID: 16867902
[TBL] [Abstract][Full Text] [Related]
18. [Clinical efficacy of lower dose rituximab for chronic refractory immune thrombocytopenic purpura].
Li Y; Wang XM; Mao M; Zhang XY; Fu L; Ai HM; Zhang LX
Zhonghua Xue Ye Xue Za Zhi; 2012 Mar; 33(3):204-6. PubMed ID: 22781608
[TBL] [Abstract][Full Text] [Related]
19. Insights on chronic-relapsing opsoclonus-myoclonus from a pilot study of mycophenolate mofetil.
Pranzatelli MR; Tate ED; Travelstead AL; Baumgardner CA; Gowda NV; Halthore SN; Kerstan P; Kossak BD; Mitchell WG; Taub JW
J Child Neurol; 2009 Mar; 24(3):316-22. PubMed ID: 19258290
[TBL] [Abstract][Full Text] [Related]
20. [Rituximab treatment of chronic idiopathic thrombocytopenic purpura. Results of a phase II study].
Meo P; Stipa E; La Presa M; Bianchi M; Di Giulio C; Stasi R; Amadori S
Recenti Prog Med; 2002; 93(7-8):421-7. PubMed ID: 12138687
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
